<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831532</url>
  </required_header>
  <id_info>
    <org_study_id>B1451018</org_study_id>
    <nct_id>NCT00831532</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function</brief_title>
  <official_title>A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic
           impairment to subjects with normal hepatic function.

        2. To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and
           subjects with normal hepatic function.

        3. To explore the pharmacokinetics of Dimebon in subjects with severely-impaired hepatic
           function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC and Cmax)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AEs, labs, ECG, vitals)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate Hepatic Impairment Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Hepatic Impairment Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <description>Dimebon 5mg in healthy controls</description>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <description>Dimebon 5mg in mild hepatic impairment patients</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <description>Dimebon 5mg in moderate hepatic impairment patients</description>
    <arm_group_label>Moderate hepatic Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <description>Dimebon 5mg in Severe Hepatic Impairment</description>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy (healthy is defined as the absence of clinically-relevant abnormalities
             identified by a detailed medical history, full physical examination, 12-lead ECG and
             clinical laboratory tests).

          -  Free of any medical or surgical conditions that might significantly interfere with
             gastrointestinal absorption, distribution, metabolism, or excretion of Dimebon.

          -  Demographically comparable to subjects with mild and moderate hepatic impairment.

          -  Subjects with hepatic impairment: Screening medical history, physical examination,
             vital signs, 12-lead ECG, and clinical laboratory tests performed within 28 days
             before the first dose of study medication, abnormal findings that are related to the
             subject's underlying condition are acceptable.

          -  Satisfy the criteria for Class A, B, or C of the modified Child-Pugh classification
             [Mild (Child-Pugh Scores 5-6 points), moderate (Child-Pugh Scores 7-9 points), and
             severe (Child-Pugh Scores &gt;9 and &lt;12 points)] within 14 days before the first dose of
             study medication.

          -  A diagnosis of hepatic impairment due to cirrhosis, not secondary to other diseases,
             which is confirmed and documented by medical history, physical examination, liver
             biopsy or hepatic ultrasound, CT scan or MRI.

        Exclusion Criteria:

          -  Subjects presenting with any of the following will not be included in the trial:CYP2D6
             PM genotype, as identified by screening genotyping.

          -  A known sensitivity to Dimebon.

          -  Exposure within the previous three months to a drug known to have a negative effect on
             skeletal muscle or reproductive organs.

          -  History of febrile illness within 5 days prior to the first dose.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, active peptic
             ulcer within last 3 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1451018&amp;StudyName=Study%20To%20Evaluate%20The%20Pharmacokinetics%2C%20Safety%2C%20And%20Tolerability%20Of%20Dimebon%20%5BPf-01913539%5D%20In%20Subjects%20With%20Hepatic%20Impairment%20And%20No</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <disposition_first_submitted>September 14, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 14, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 16, 2009</disposition_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Dimebon Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

